(Q34642515)

3 August 2017

1 reference

title

Beta-agonist intrinsic efficacy: measurement and clinical significance (English)

1 reference

3 August 2017

1

Nicola A Hanania

1 reference

3 August 2017

4

Burton F Dickey

1 reference

3 August 2017

Amir Sharafkhaneh

2

1 reference

3 August 2017

Roger Barber

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

3 August 2017

published in

1 reference

3 August 2017

volume

165

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

1353-1358

1 reference

Long-acting inhaled beta2-agonists in asthma therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Long-acting inhaled beta(2)-agonist therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

International trends in asthma mortality: 1970 to 1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Beta-adrenergic receptors and their regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Inhibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Comparative rates of desensitization of beta-adrenergic receptors by the beta-adrenergic receptor kinase and the cyclic AMP-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Partial agonists and G protein-coupled receptor desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

beta(2)-adrenergic receptor pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Continuous Isoproterenol Inhalation Therapy in Children with Severe Asthmatic Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2109060

21 January 2018

Identifiers

DOI

10.1164/RCCM.2109060

1 reference

3 August 2017

1 reference